ImmunoGen, Inc. Appoints Theresa Wingrove, Ph.D., as Vice President, Regulatory Affairs
19 January 2011 - 1:14AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops targeted antibody-based anticancer products using its
antibody expertise and Targeted Antibody Payload (TAP) technology,
today announced the appointment of Theresa G. Wingrove, Ph.D. as
Vice President of Regulatory Affairs. Dr. Wingrove will be
responsible for leading the regulatory development of the Company’s
product candidates and directing the regulatory submissions
prepared by ImmunoGen in support of the Company’s own programs and
those of its partners. Dr. Wingrove reports to Daniel Junius,
President and Chief Executive Officer.
“Theresa brings to ImmunoGen a wealth of regulatory experience
in the development of new healthcare products,” commented Mr.
Junius. “Her addition to our team is particularly timely in light
of our programs to aggressively advance our lead compound – IMGN901
– and our expectation that we’ll double the number of compounds we
have in the clinic by early 2012.”
Dr. Wingrove joins ImmunoGen with over twenty years of
regulatory and clinical management experience in the healthcare
industry. Before joining ImmunoGen, she was the vice president of
regulatory and clinical affairs at Histogenics, where her
responsibilities included authoring and gaining approval of a SPA
for a Phase III trial for a novel biologic and other regulatory
responsibilities in the US and Europe. Prior to that, she was the
senior director of regulatory and clinical affairs at MediSpectra,
where she was responsible for the full spectrum of regulatory
support – from start of clinical testing through marketing approval
– for a novel cancer diagnostic product. Prior to joining
MediSpectra, Dr. Wingrove was at Pfizer-Infusaid for over ten
years, during which time she executed the clinical and regulatory
programs associated with the company’s combination products. She
holds a BS in Biochemistry from Brown University and a doctorate in
Biochemical Toxicology from the University of Rochester.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company's expertise in tumor biology, monoclonal antibodies and
potent cancer-cell killing agents. The Company's TAP technology
uses monoclonal antibodies to deliver one of ImmunoGen's
proprietary cancer-cell killing agents specifically to tumor cells.
There are currently seven TAP compounds in the clinic, with a
wealth of clinical data reported with the technology. ImmunoGen’s
collaborative partners include Amgen, Bayer Schering Pharma, Biogen
Idec, Biotest, Genentech (a member of the Roche Group), Novartis,
and sanofi-aventis. The most advanced compound using ImmunoGen's
TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing
through the Company's collaboration with Genentech. More
information about ImmunoGen can be found at www.immunogen.com.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including IMGN901 and ImmunoGen’s
current preclinical candidates, including risks related to
uncertainties around preclinical studies and clinical trials
conducted and their timings and results. A review of these risks
can be found in ImmunoGen’s Annual Report on Form 10-K for the
fiscal year ended June 30, 2010 and other reports filed with the
Securities and Exchange Commission.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024